January 29, 2024

National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai-400051

Symbol: **ORCHPHARMA**

BSE Limited
Phiroze Jeejeebhoy Towers, Dalal Street
Fort, Mumbai-400001

Scrip Code: **524372**

Subject: Press Release – Orchid Pharma Limited ("the Company")

Dear Sir/Madam,

In accordance to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Schedule III, kindly find enclosed the Press Release being released titled **"Orchid Pharma's 'Exblifep' granted European Medicines Agency approval - A landmark achievement for India's pharmaceutical Industry"**

You are requested to take the above information on your record.

Thanking You,

For **Orchid Pharma Limited**

KAPIL DAYYA

Digitally signed by KAPIL DAYYA
DN: c=IN, o=Person, ou=Others, postalCode=201102, l=Ghaziabad, st=Uttar Pradesh, street=238, NAIPURA LONI, GHAZIABAD LONI, title=2894, 2.5.4.20=ab829c22de1effbdfc0b22c16561 49c2ef30e8aef4671d2952fe3892 86e22c52, serialNumber=e27acd3bad231a5f8fbc79a89feead642f7b38cfe6a6c40c3f8a1f8a46b16ed, email=kapildayya@gmail.com, cn=KAPIL DAYYA
Date: 2024.01.29 17:27:08 +05'30'

Kapil Dayya
Company Secretary & Compliance Officer

Encl: As Above

Press release

Orchid Pharma's 'Exblifep' granted European Medicines Agency approval - A landmark achievement for India's pharmaceutical Industry

- The primary novel invention component of Exblifep – Enmetazobactam is the first drug invented in India to have achieved this landmark
- It is a significant development in addressing the global need for affordable and efficacious drugs to combat AMR (Anti-Microbial Resistance)
- Exblifep has received EMA's recommendation for marketing authorization for use in treatment of complicated Urinary Tract Infections (cUTI), pneumonia, and bacteremia due to ESBL producing pathogens

New Delhi, 29 January 2024: Orchid Pharma, based in Chennai, India, has achieved a significant breakthrough with its antibiotic invention, 'Exblifeb,' which incorporates Enmetazobactam, the first completely invented-in-India Beta Lactamase Inhibitor. This pioneering drug recently received the European Medicines Agency's (EMA) recommendation for marketing authorization, marking the first instance of an Indian-invented drug reaching this stage of clinical development.

Designed to address the global challenge of Anti-Microbial Resistance (AMR), 'Exblifeb' demonstrates remarkable efficacy in treating complicated Urinary Tract Infections (cUTI), pneumonia, and bacteremia caused by Extended Spectrum Beta-lactamase producing pathogens. During clinical trials, 'Exblifeb' exhibited superior performance compared to the current go-to drug, Piperacillin + Tazobactam. It is positioned as a potent, cost-effective, and Carbapenem-sparing therapy, offering a viable solution in the fight against rising AMR.

This milestone not only positions 'Exblifeb' as a front-runner in combating AMR but also underscores the urgent need for effective solutions. According to the Global Burden of Disease Study, infections caused by antimicrobial-resistant bacteria led to the direct death of 1.27 million people in 2019. 'Exblifeb,' with its unique Indian origin and superior clinical performance, has the potential to become a standard of care worldwide in addressing this global health crisis.

Mr Manish Dhanuka, Managing Director - Orchid Pharma, celebrating this development said, “with the potential to save thousands of lives globally, this approval by EMA is a testament to Indian ingenuity. It is also a matter of great pride that as the pharmacy of the world, India has now developed a new drug for the first time.”

Enmetazobactam was invented in India by Orchid and then out-licensed to Allecra Therapeutics for further development.

Orchid Pharma Limited.

Established in 1992 as an export-oriented unit (EOU), Orchid Pharma Ltd. (Orchid) is a vertically integrated Company spanning the entire pharmaceutical value chain with established credentials in research, manufacturing, and marketing.

Orchid, is the only Indian Pharmaceutical Company, to ever have invented a New Chemical Entity (NCE, also colloquially called New Drug). The molecule is out licensed (on Royalty model) and now under worldwide New Drug Approval Process.

Orchid is a pioneer in Production of Quality Cephalosporins especially the Sterile Products, for which it is the one out of the only three USFDA approved facilities in the world, and the only one from India. Besides this, the facility has other approvals like EU GMP, ANVISA and PMDA.

Dhanuka Group acquired Orchid Pharma Ltd. through CIRP (Corporate Insolvency Resolution Process) under IBC (Insolvency and Bankruptcy Code) on 31st March 2020. Since, then the Company has gone through a transformation going from a negative EBIDTA to healthy positive numbers.